Phillygenin protects against lipopolysaccharide-induced acute lung injury by acting as a PXR agonist via NF-κB inhibition.

Wang CJ, Dai MD, Tan YJ, Lv CJ, Song Y, Zhai SP, Chen Z

Open source

DOI
10.1038/s41598-026-66771-z
Published
2026 Aug 29
Container
Scientific reports
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41598-026-66771-z,
  title = {Phillygenin protects against lipopolysaccharide-induced acute lung injury by acting as a PXR agonist via NF-κB inhibition.},
  author = {Wang CJ and Dai MD and Tan YJ and Lv CJ and Song Y and Zhai SP and Chen Z},
  year = {2026},
  journal = {Scientific reports},
  doi = {10.1038/s41598-026-66771-z},
  url = {https://doi.org/10.1038/s41598-026-66771-z}
}

RIS

TY  - JOUR
TI  - Phillygenin protects against lipopolysaccharide-induced acute lung injury by acting as a PXR agonist via NF-κB inhibition.
AU  - Wang CJ
AU  - Dai MD
AU  - Tan YJ
AU  - Lv CJ
AU  - Song Y
AU  - Zhai SP
AU  - Chen Z
PY  - 2026
JO  - Scientific reports
DO  - 10.1038/s41598-026-66771-z
UR  - https://doi.org/10.1038/s41598-026-66771-z
ER  - 

APA

CJ, W., MD, D., YJ, T., CJ, L., Y, S., SP, Z., & Z, C. (2026). Phillygenin protects against lipopolysaccharide-induced acute lung injury by acting as a PXR agonist via NF-κB inhibition.. Scientific reports. https://doi.org/10.1038/s41598-026-66771-z

Source records